Upadacitinib
Treatment for Ankylosing Spondylitis
Typical Dosage: 15mg or 30mg orally once daily
Effectiveness
70%
Safety Score
55%
Clinical Trials
5
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
15mg or 30mg orally once daily
Time to Effect
1-2 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50,000
Monitoring:$500
Side Effect Mgmt:$500
Total Annual:$51,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$180,000/QALY
QALYs Gained
1.3
Outcome-Based Costs
Cost per Responder
$68,000
Cost per Remission
$134,210
Comparison vs Adalimumab
Cost Difference
+$20,000/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Upadacitinib Outcomes
for Ankylosing Spondylitis
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+75%
Remission Rate
+38%
Common Side Effects
Upper respiratory tract infections
+20%
Nasopharyngitis
+15%
Nausea
+10%
Increased CPK
+5%
Acne
+5%
Serious infections
+3%
Major adverse cardiovascular events (MACE)
+1%
Venous thromboembolism (VTE)
+1%
Malignancies
+0.5%
Gastrointestinal perforation
+0.1%
Sources:
Active Clinical Trials
3 active trials recruiting for Upadacitinib in Ankylosing Spondylitis
Korean College of Rheumatology Biologics and Targeted Therapy Registry
NCT01965132RECRUITING
10K participants
OBSERVATIONAL
Seoul, South Korea
Started: Dec 1, 2012
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
NCT04541810RECRUITING
3.6K participants
OBSERVATIONAL
Busan, South Korea +115 more
Started: Jan 26, 2021
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
NCT07138898NOT YET RECRUITINGPHASE2
80 participants
INTERVENTIONAL
New York, United States
Started: Sep 1, 2025
Completed Clinical Trials
2 completed trials for Upadacitinib in Ankylosing Spondylitis
A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
NCT03178487COMPLETEDPHASE2
187 participants
INTERVENTIONAL
Phoenix, United States +100 more
Started: Oct 24, 2017
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
NCT04169373COMPLETEDPHASE3
734 participants
INTERVENTIONAL
Flagstaff, United States +211 more
Started: Nov 26, 2019